SCHEMBL4088646

SCHEMBL4088646

OCCCSCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.57
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALDH1A1 P00352 3/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
ALPL P05186 1/20 0.46
ALPI P09923 1/20 0.46
ALPG P10696 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
PTGER1 P34995 1/20 0.44
PTGER4 P35408 1/20 0.44
PTGER3 P43115 1/20 0.44
PTGER2 P43116 1/20 0.44
TSHR P16473 1/20 0.42
IDO1 P14902 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11413592 0.94 CYP2C19 (0.55) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23603829 0.92 CYP2C19 (0.53) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1008355 0.92 CYP2C19 (0.53) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL16371587 0.92 CYP2C19 (0.53) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1149087 0.86 CYP2C19 (0.61) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7909121 0.86 CYP2C19 (0.59) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6306047 0.86 CYP2C19 (0.59) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL28965534 0.84 CYP2C19 (0.57) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL31163814 0.83 PTGER1 (0.46) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL3078147 0.81 CYP2C19 (0.64) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670460-B1 PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2014-11-26 EP disclosed
US-7517900-B2 Pyrazole derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-14 US disclosed
US-20050080087-A1 Pyrazole derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-04-14 US disclosed
US-4659370-A Substituted phenoxypropionates and herbicidal compositions containing same and their herbicidal use NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1987-04-21 US disclosed
US-4614536-A Certain pyridyloxy-phenoxy-propionate derivatives, herbicidal compositions containing same and their herbicidal method of use NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) 1986-09-30 US disclosed
EP-0092112-B1 SUBSTITUTED PHENOXY PROPIONATES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1985-03-06 EP disclosed
US-4500346-A Substituted phenoxypropionates and herbicidal compositions containing same and their herbicidal use NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1985-02-19 US disclosed
EP-0092112-A1 Substituted phenoxy propionates NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1983-10-26 EP disclosed
US-4033965-A DISPERSE CIBA-GEIGY CORPORATION (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080087-A1 Pyrazole derivatives as cannabinoid receptor modulators CNR1, CNR2, NPY1R CYP2C19 216/4885CYP1A2 299/4885CYP3A4 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.